Effectiveness of Levidex in Improving Quality of Life for People with Multiple Sclerosis: Results of a Clinical Trial
Background
Multiple Sclerosis (MS) significantly impacts patients’ quality of life (QoL). Levidex, a digital health application based on cognitive behavioral therapy (CBT) principles, was tested in a randomized controlled trial to examine its effects on MS-related QoL over 6 months.
Methods
Participants with MS were randomly assigned to receive standard care + levidex or standard care with web-adapted material. The primary outcome was MS-related QoL after 6 months, measured by the Hamburg Quality of Life Questionnaire in MS (HAQUAMS).
Results
After 6 months, the group using levidex showed significantly higher MS-related QoL, fewer sick days, and higher levels of daily activities compared to the control group. Safety analyses showed no adverse events and good satisfaction.
Conclusions
Levidex facilitated clinically relevant improvements in MS-related QoL, reduced sick days, and enhanced activity in people with MS over 6 months. It can serve as an effective non-pharmacological adjunctive treatment element to standard care and help improve QoL among people with MS.
Clinical Trials Registration
Registered on 22.09.2020 at the German Clinical Trials Register DRKS00023023.
AI-Driven Solutions for Healthcare
Clinical trials are essential for developing safe and effective treatments. Our AI-driven platform, DocSym, consolidates ICD-11 standards, clinical protocols, and research into a single, easily accessible knowledge base for clinicians.
In today’s healthcare environment, our mobile apps support scheduling, monitoring treatments, and telemedicine, making it easier to manage patient care and expand services digitally. By using AI, clinics can enhance their workflows and improve patient outcomes, reducing paper routine.
Learn more about how we can help at aidevmd.com.
